{"transactions":[{"id":3180281,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T21:22:35.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":71303,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":201410,"source":{"system":"sec-edgar","filing":"0001209191-20-023807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023807/doc4.xml","form_type":"4"}},{"id":3180280,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T21:22:35.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":220496,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":328609,"source":{"system":"sec-edgar","filing":"0001209191-20-023807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023807/doc4.xml","form_type":"4"}},{"id":3180279,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T21:22:35.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":63844,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. (\"Menlo\") issued additional shares of its common stock pursuant to certain contingent stock rights (\"CSRs\") issued in connection with the March 9, 2020 merger (the \"Merger\") of Menlo and Foamix Pharmaceuticals Ltd. (\"Foamix\"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the \"Final Exchange Ratio\"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) awards that were received by the reporting person as a result of the foregoing."}],"balance_after":130107,"source":{"system":"sec-edgar","filing":"0001209191-20-023807","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120023807/doc4.xml","form_type":"4"}},{"id":3215136,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-03-11T21:57:14.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":29481,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":29481,"derivative":{"exercise_price":8.48,"exercise_date":"2020-03-09","expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":29481},"source":{"system":"sec-edgar","filing":"0001209191-20-018227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018227/doc4.xml","form_type":"4"}},{"id":3215135,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-03-11T21:57:14.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":48667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021."}],"balance_after":48667,"derivative":{"exercise_price":7.92,"expiration_date":"2027-07-13","underlying":"Common Stock","underlying_shares":48667},"source":{"system":"sec-edgar","filing":"0001209191-20-018227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018227/doc4.xml","form_type":"4"}},{"id":3215134,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-03-11T21:57:14.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":15994,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":15994,"derivative":{"exercise_price":9.93,"exercise_date":"2020-03-09","expiration_date":"2024-12-29","underlying":"Common Stock","underlying_shares":15994},"source":{"system":"sec-edgar","filing":"0001209191-20-018227","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018227/doc4.xml","form_type":"4"}},{"id":3215133,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T21:57:14.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":34960,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":66263,"source":{"system":"sec-edgar","filing":"0001209191-20-018227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018227/doc4.xml","form_type":"4"}},{"id":3215132,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T21:57:14.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":108113,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":108113,"source":{"system":"sec-edgar","filing":"0001209191-20-018227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018227/doc4.xml","form_type":"4"}},{"id":3215131,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-11T21:57:14.000Z","date":"2020-03-09","kind":"grant","acquired":true,"shares":31303,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in or in connection with the merger of Foamix Pharmaceuticals Ltd.  (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. (\"Menlo\"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020."}],"balance_after":31303,"source":{"system":"sec-edgar","filing":"0001209191-20-018227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120018227/doc4.xml","form_type":"4"}},{"id":3215004,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:39:28.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":49766,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019."}],"balance_after":0,"derivative":{"exercise_price":5.02,"expiration_date":"2028-05-08","underlying":"Ordinary Shares","underlying_shares":49766},"source":{"system":"sec-edgar","filing":"0001209191-20-018197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018197/doc4.xml","form_type":"4"}},{"id":3215003,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:39:28.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":82153,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021."}],"balance_after":0,"derivative":{"exercise_price":4.69,"expiration_date":"2027-07-13","underlying":"Ordinary Shares","underlying_shares":82153},"source":{"system":"sec-edgar","filing":"0001209191-20-018197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018197/doc4.xml","form_type":"4"}},{"id":3215002,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:39:28.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":27000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date)."}],"balance_after":0,"derivative":{"exercise_price":5.88,"expiration_date":"2024-12-29","underlying":"Ordinary Shares","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001209191-20-018197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018197/doc4.xml","form_type":"4"}},{"id":3215001,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:39:28.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":59016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents Foamix restricted stock unit awards (\"Foamix RSUs\") that were outstanding immediately prior to the Effective Time, each of which by its terms represented a contingent right to receive one Foamix Share. Each Foamix RSU was assumed by Menlo and converted into a restricted stock unit award relating to Menlo Common Stock (an \"Adjusted RSU Award\") and has the same terms and conditions as applied to the Foamix RSU immediately prior to the Effective Time. The Adjusted RSU Award will settle in the number of shares of Menlo Common Stock equal to the product obtained by multiplying (i) the number of Foamix Shares subject to the Foamix RSU immediately prior to the Effective Time by (ii) the Exchange Ratio. If the CSRs become convertible, each person holding a Foamix RSU immediately prior to the Effective Time will get additional Adjusted RSU Awards based on the additional shares of Menlo Common Stock that each ordinary Foamix Share will get upon conversion of a CSR."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-018197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018197/doc4.xml","form_type":"4"}},{"id":3215000,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:39:28.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":182500,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":59016,"source":{"system":"sec-edgar","filing":"0001209191-20-018197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018197/doc4.xml","form_type":"4"}},{"id":3214999,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:39:28.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":52842,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."}],"balance_after":241516,"source":{"system":"sec-edgar","filing":"0001209191-20-018197","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018197/doc4.xml","form_type":"4"}},{"id":3230631,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-03T16:32:18.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":42493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021."}],"balance_after":111858,"source":{"system":"sec-edgar","filing":"0001209191-20-015195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120015195/doc4.xml","form_type":"4"}},{"id":3379732,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2019-11-05T16:32:52.000Z","date":"2019-11-04","kind":"exercise","acquired":false,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":0,"derivative":{"exercise_price":0.62,"exercise_date":"2004-01-01","expiration_date":"2019-11-25","underlying":"Ordinary Shares","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0001209191-19-055210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119055210/doc4.xml","form_type":"4"}},{"id":3379731,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-11-05T16:32:52.000Z","date":"2019-11-04","kind":"exercise","acquired":true,"shares":32500,"price":0.62,"value":20150.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":182500,"source":{"system":"sec-edgar","filing":"0001209191-19-055210","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119055210/doc4.xml","form_type":"4"}},{"id":3391536,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2019-10-17T16:11:34.000Z","date":"2019-10-15","kind":"exercise","acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":32500,"derivative":{"exercise_price":0.62,"exercise_date":"2004-01-01","expiration_date":"2019-11-25","underlying":"Ordinary Shares","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-19-053413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119053413/doc4.xml","form_type":"4"}},{"id":3391535,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-10-17T16:11:34.000Z","date":"2019-10-15","kind":"exercise","acquired":true,"shares":90000,"price":0.62,"value":55800.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001209191-19-053413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119053413/doc4.xml","form_type":"4"}},{"id":3438454,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2019-08-14T14:59:45.000Z","date":"2019-08-13","kind":"exercise","acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":122500,"derivative":{"exercise_price":0.62,"exercise_date":"2004-01-01","expiration_date":"2019-11-25","underlying":"Ordinary Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001178913-19-002190","document":"zk1923414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891319002190/zk1923414.xml","form_type":"4"}},{"id":3438453,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-08-14T14:59:45.000Z","date":"2019-08-13","kind":"exercise","acquired":true,"shares":60000,"price":0.62,"value":37200.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001178913-19-002190","document":"zk1923414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891319002190/zk1923414.xml","form_type":"4"}},{"id":3518001,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-20T18:34:35.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":56391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020."}],"balance_after":69365,"source":{"system":"sec-edgar","filing":"0001209191-19-031529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119031529/doc4.xml","form_type":"4"}},{"id":3867849,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2018-07-13T16:08:47.000Z","date":"2018-07-13","kind":"exercise","acquired":false,"shares":1616,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on July 13, 2018 and 6.25% every three months thereafter) ending July 13, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on July 13, 2018 and 6.25% every three months thereafter) ending July 13, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This class of restricted share units is included in Column 5 of Table I above."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":1616},"source":{"system":"sec-edgar","filing":"0001178913-18-002082","document":"zk1821887.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318002082/zk1821887.xml","form_type":"4"}},{"id":3867848,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-07-13T16:08:47.000Z","date":"2018-07-13","kind":"exercise","acquired":true,"shares":1616,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,508 ordinary shares previously reported in Table I of the reporting person's Form 4 (ii) 1,616 ordinary shares underlying restricted share units that vested on July 13, 2018 (iii) 4,850 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security."}],"balance_after":12974,"source":{"system":"sec-edgar","filing":"0001178913-18-002082","document":"zk1821887.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318002082/zk1821887.xml","form_type":"4"}},{"id":3912013,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-05-31T16:51:10.000Z","date":"2018-05-13","kind":"other","acquired":false,"shares":6224,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.04,"exercise_date":"2013-05-14","expiration_date":"2018-05-13","underlying":"Ordinary Shares","underlying_shares":6224},"source":{"system":"sec-edgar","filing":"0001178913-18-001826","document":"zk1821767.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318001826/zk1821767.xml","form_type":"4"}},{"id":3912012,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-31T16:51:10.000Z","date":"2018-05-13","kind":"sale","acquired":false,"shares":6164,"price":5.089,"value":31368.596,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 13, 2018, warrants held by Mr. Hirsch for the purchase of up to 6,224 ordinary shares of the Issuer for $5.04 per share were automatically exercised on a net-issuance (cashless) basis upon their expiration, in accordance with their terms. This cashless exercise resulted in the Issuer withholding 6,164 of the warrant shares to pay the exercise price and issuing to Mr. Hirsch the remaining 60 shares."}],"balance_after":6508,"source":{"system":"sec-edgar","filing":"0001178913-18-001826","document":"zk1821767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318001826/zk1821767.xml","form_type":"4"}},{"id":3912011,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-31T16:51:10.000Z","date":"2018-05-13","kind":"other","acquired":true,"shares":6224,"price":5.04,"value":31368.96,"ownership":{"direct":true},"balance_after":12672,"source":{"system":"sec-edgar","filing":"0001178913-18-001826","document":"zk1821767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318001826/zk1821767.xml","form_type":"4"}},{"id":3938347,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":149951,"kind":"person","name":"Hirsch Stanley","position":1,"cik":"0001727864","reported_name":"Hirsch Stanley","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2018-05-10T17:36:16.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":49766,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 8, 2019."}],"balance_after":49766,"derivative":{"exercise_price":5.02,"expiration_date":"2028-05-08","underlying":"Ordinary Shares","underlying_shares":49766},"source":{"system":"sec-edgar","filing":"0001178913-18-001603","document":"zk1821663.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318001603/zk1821663.xml","form_type":"4"}}]}